Clinical and metabolic characteristics of males with early-onset androgenetic alopecia

Background: Men with early-onset androgenetic alopecia (AGA) often have an abnormal hormonal milieu. Objective: To ascertain the clinico-phenotypic characteristics and the prevalence of hormonal and metabolic changes in men with early-onset AGA. Methods: Consecutive male patients less than 30 years of age with a Norwood-Hamilton grade ?3 AGA were recruited in this comparative cross-sectional study. After endocrine evaluation they were classified into two groups, that is, Group A consisting of subjects with an altered hormonal profile and Group B with normal hormonal profiles. The groups were assessed for differences in disease phenotype and severity (Norwood-Hamilton grade), insulin resistance and parameters of metabolic syndrome (ATP III guidelines). Results: Altered hormonal profiles were seen in 34 of the 100 subjects with AGA, while insulin resistance and metabolic syndrome were noted in 44 and 26 respectively. Altered hormonal profiles were significantly associated with insulin resistance and severe alopecia (grade 4 and above Hamilton-Norwood Scale). Insulin resistant Group A patients had a significantly higher prevalence of severe alopecia (>grade 4) (P = 0.0036). The prevalence of metabolic syndrome was similar in both groups. Limitation: The cross sectional study design was a drawback of this study. Further, a control arm without AGA was not included and the sample size of 100 was selected arbitrarily. Conclusion: An altered hormonal profile and insulin resistance was noted in a third of the males with early-onset AGA. Subjects with altered hormonal profiles had a higher prevalence of insulin resistance and were likely to have severe grades of AGA

Female-pattern hair loss: therapeutic update

Abstract Female androgenetic alopecia or female-pattern hair loss (FPHL) is highly prevalent and has a great impact on the quality of life. The treatment is a routine challenge in dermatological practice, as many therapeutic options have a limited level of evidence and often do not meet patients expectations. Lack of knowledge of the pathogenesis of the hair miniaturization process and the factors that regulate follicular morphogenesis restricts the prospect of innovative therapies. There is also a lack of randomized, controlled studies with longitudinal follow-up, using objective outcomes and exploring the performance of the available treatments and their combinations. Topical minoxidil, which has been used to treat female pattern hair loss since the 1990s, is the only medication that has a high level of evidence and remains the first choice. However, about 40% of patients do not show improvement with this treatment. In this article, the authors critically discuss the main clinical and surgical therapeutic alternatives for FPHL, as well as present camouflage methods that can be used in more extensive or unresponsive cases.

Unscrewing the DHT-Blocking Properties of Allium cepa Extract: Virtual Screening of Active Compounds Against 5-Alpha Reductase and Evaluation of ADME/T Properties of Compounds

Androgenetic alopecia (AGA) occurs in genetically prone men and women and is defined by pattern-related, non-scarring hair follicle shrinkage. It is estimated that up to 80% of men and 50% of women will be affected by AGA at some stage in their lives. The underlying pathophysiology may be traced back to the enzyme 5-alpha-reductase, which is responsible for the conversion of testosterone to dihydrotestosterone (DHT), a more powerful androgen, and its accumulation in hair follicles leads to hair loss. The therapeutic approach for treating AGA mainly relies on the inhibition of 5-alpha- reductase. Allium cepa (onion) extract is in trend as a natural remedy for the treatment of AGA. The study aims at in-silico and ADME/T analysis of active compounds present in onion extract against 5-alpha-reductase to evaluate and visualize protein-ligand interaction.

THE ROLE OF PLATELET-RICH PLASMA IN ANDROGENETIC ALOPECIA: A COMPREHENSIVE NARRATIVE REVIEW

Platelet-rich plasma (PRP) is a promising treatment in regenerative medicine for androgenetic alopecia (AGA). PRP, derived from the patient's blood, contains a concentrated platelet fraction rich in growth factors and bioactive molecules that aid in tissue repair and wound healing. When PRP is administered, these factors are released, stimulating hair growth and regeneration. PRP's mechanism of action involves the release of growth factors like PDGF, TGF-β, VEGF, and IGF, which promote cell proliferation, activate dormant hair follicles, and induce hair cycle growth. PRP also reduces inammation, promotes angiogenesis, and may inhibit 5-alpha reductase activity, which contributes to AGA. By understanding these mechanisms, PRP can be optimized for effective hair restoration therapies in AGA

Advances in stem cells treatment of androgenetic alopecia / 中国药科大学学报

@#Androgenetic alopecia (AGA) is the most prominent type of progressive hair loss in humans.At present, medication is the main treatment for AGA, however, drug therapy has significant side-effects. Stem cells provide a new strategy for the treatment of AGA, because of their role in tissue repair and maintenance of microenvironmental homeostasis.This paper reviews the pathogenesis of AGA, discusses the defects of traditional drug therapy,and discusses the research progress of stem cells and stem cell derivatives in the treatment of AGA, in order to provide a comprehensive review of the prospects of stem cell therapy for AGA.

Nailfold capillaroscopy alterations in androgenetic alopecia: A cross-sectional study

Background: Androgenetic alopecia is considered to be an independent predictor of mortality from diabetes mellitus and heart disease. However, whether androgenetic alopecia causes changes in microcirculation is unknown. Objective: The objective of the study was to investigate whether alterations in nailfold capillaries occur in androgenetic alopecia patients. Methods: The nailfold capillaroscopy images of androgenetic alopecia patients and matched controls were collected and analyzed. Results: The frequencies of avascular areas, dilated, bushy and bizarre capillaries and capillary disorganization, nailfold capillaroscopy scores of 2 or scores both 2 and 3 were significantly higher in the androgenetic alopecia group than in the healthy controls (9.0% vs. 0%, 57.7% vs. 19.2%, 3.8% vs. 0%, 2.8% vs. 1.3%, 3.8% vs. 0%, 38.5% vs. 12.8% and 39.7% vs. 12.8%, respectively). Limitations: The results of this study may be biased on account of the limited sample size or the presence of an undiagnosed disease in participants which could alter the nailfold capillaries. Conclusion: Bushy, bizarre and dilated capillaries, capillary disorganization, avascular areas and nailfold capillaroscopy scores of 2 or 2 and 3 were more common in androgenetic alopecia patients than in healthy controls. These findings indicate that abnormalities in microcirculation may be involved in androgenetic alopecia

Plasma rico en plaquetas en el tratamiento de la alopecia androgenética: estudio de serie de casos / Facial rejuvenation with autologous platelet rich plasma

Introducción: La alopecia androgenética es el tipo más prevalente de pérdida de pelo. Se manifiesta a edades tempranas y es más frecuente en el sexo masculino. Objetivo: Evaluar los resultados de la infiltración del plasma rico en plaquetas en una serie de casos con alopecia androgenética. Métodos: Se realizó un estudio observacional, descriptivo y longitudinal en una serie de casos, que incluyó 56 pacientes con diagnóstico clínico y dermatoscópico de alopecia androgenética que recibieron tratamiento con plasma rico en plaquetas en el área centro de la ciudad Sancti Spíritus, durante el período de julio 2015 a marzo de 2021. Se inyectaron 6 mL por vía intradérmica de plasma rico en plaquetas en el área afectada con múltiples inyecciones en patrón lineal a un cm de separación bajo el cuidado aséptico. El tratamiento se repitió cada 3 semanas por 8 sesiones. Las variables principales fueron la prueba de tracción pelo y eventos adversos. Resultados: Predominó el sexo masculino, las edades entre 19 y 51 años. El tiempo de evolución osciló entre 1 y 20 meses, la mayoría tenía antecedentes patológicos familiares de alopecia. Predominó el patrón III de Halminton Norwood. Como eventos adversos se presentaron dolor, ardor y eritema en el sitio de inyección en todos los casos. Conclusiones: La prueba de tracción del pelo en la mayoría de los pacientes tratados con plasma rico en plaquetas fue negativa al culminar el tratamiento(AU)

Introduction: Androgenetic alopecia is the most prevalent type of hair loss, it can be manifested at an early age, being more frequent in males. Objective: To evaluate the results of the infiltration of platelet-rich plasma in a series of cases with androgenetic alopecia. Methods: An observational, descriptive and longitudinal study was carried out in a series of cases, which included 56 patients with a clinical and dermatoscopic diagnosis of androgenetic alopecia who received treatment with platelet-rich plasma in the downtown area of the city of Sancti Spíritus, during the period from July 2015 to March 2021. 6 mL of platelet-rich plasma were injected intradermally into the affected area with multiple injections in a lineal pattern one cm apart under aseptic care. The treatment was repeated every 3 weeks for 8 sessions. The main variables were the hair pull test and adverse events. Results: Male sex predominated, ages between 19 and 51 years, evolution time ranged between 1 and 20 months, most had a family pathological history of alopecia, Halminton Norwood pattern III prevailed. Adverse events included pain, burning, and erythema at the injection site in all cases. Conclusions: The hair-pull test in most patients treated with platelet-rich plasma was negative at the end of treatment(AU)

Pediatric androgenetic alopecia: a retrospective review of clinical characteristics, hormonal assays and metabolic syndrome risk factors in 23 patients

Abstract Background Androgenetic alopecia in the pediatric population is rarely discussed in the literature. Although the prevalence of the metabolic syndrome is increased in patients with early-onset androgenetic alopecia, the presence of metabolic syndrome risk factors in pediatric androgenetic alopecia is unknown. Objective To evaluate the demographics, medical and family histories, clinical and trichoscopic features, androgenic hormones, and metabolic syndrome risk factors in pediatric androgenetic alopecia. Methods The medical reports of pediatric patients with androgenetic alopecia were reviewed. Results The study included 23 patients (12 females and 11 males) with a mean age of 15,3 ± 2,1 years. Sixteen patients had adolescent androgenetic alopecia and seven, had childhood alopecia. Nine patients reported a family history, all of whom had adolescent androgenetic alopecia. Hyperandrogenism was noted in three patients with adolescent androgenetic alopecia. The most common hair loss pattern was diffuse thinning at the crown with preservation of the frontal hairline which was noted in 10 patients (43.5%), six of whom were males. Fourteen patients (60.9%) had at least one metabolic syndrome risk factor. The most common risk factor was obesity or overweight (47.8%) followed by insulin resistance (21.7%), high fasting blood glucose (13%), high blood pressure (4.4%) and lipid abnormalities (4.4%). Study limitations Retrospective study; lack of a control group. Conclusion Pediatric androgenetic alopecia is often associated with metabolic syndrome risk factors. Therefore, androgenetic alopecia in the pediatric population may indicate a future metabolic syndrome which warrants an accurate and prompt diagnosis for early screening and treatment.

A case of cicatricial female pattern hair loss / 中华皮肤科杂志

A case of cicatricial female pattern hair loss was reported. A 36-year-old female patient presented with gradually aggravated hair loss for more than 10 years. Skin examination showed diffuse hair thinning on the scalp, thin and soft hairs, and some pencil eraser-sized areas of focal atrichia. TrichoScan examination revealed markedly decreased hair density on the forehead, variability in hair diameter greater than 20%, and increased proportions of vellus hairs. Dermoscopic examination showed increased numbers of vellus hairs, plenty of focal atrichia areas measuring 3 - 5 mm in diameter, loss of some follicular ostia, and confluent white dots. Histopathological examination of vertical and transverse scalp sections showed predominantly distributed miniaturized hair follicles with lichenoid folliculitis around the infundibulum and isthmus, concentrically layered perifollicular fibrosis, a marked decrease in the number of hair follicles compared with healthy people of the same age, increased proportions of vellus hairs, a large number of miniaturized hair follicles and follicular streamers, and formation of follicular micro-scars. The patient was diagnosed with cicatricial female pattern hair loss. She received topical treatment with 5% minoxidil liniment once a day, and alternate treatment with topical tacrolimus ointment and clobetasol propionate ointment, as well as oral spironolactone at a dose of 20 mg twice a day and compound glycyrrhizin capsules at a dose of 50 mg thrice a day. After half a year of treatment, there was no marked aggravation of hair loss, and the follow-up continued.

A Case of Androgenetic Alopecia (AGA) Successfully Treated with Combined Treatment of Basalt Stone Treatment and Placenta Extract: A Case Report / 日本補完代替医療学会誌

Improvement of hair thinning was observed after a novel treatment course involving basalt stone and placental extract application in a patient of androgenetic alopecia. The patient was resistant to the general home care treatment. The response to the new treatment may be attributed to the decreased scalp hardness secondary to the improved blood circulation after basalt stone massage and the hair growth-promoting action of the placental extract. Furthermore, recurrence of hair thinning was observed after suspension of this treatment; however, this hair thinning improved when the treatment was resumed.

Research advance in androgenetic alopecia in 2020 / 中华皮肤科杂志

Androgenetic alopecia is a distinctive condition associated with genetic factors and effect of androgens, usually adversely affects the appearance and mental health of patients. This review summarizes research progress in the pathogenesis, diagnosis, evaluation and clinical treatment of androgenetic alopecia in 2020.

Platelet Rich Plasma in Androgenetic Alopecia- A Prospective Study.

Androgenetic alopecia (AGA) is a common cause of hair loss in males and this has profound effect on the quality of life of patients. There are various treatment modalities and Platelet Rich Plasma (PRP) is one with promising effect in various studies. It contains platelets at a concentration of more than one million and contains various growth factors such as platelet-derived growth factors, vascular endothelial growth factors, epidermal growth factors which promote hair growth. As it is autologous, it has very few side effects.METHODS20 patients with AGA belonging to the age group 18- 40 years, Hamilton Norwood Stage 1-4 who attended dermatology OPD were included. Dermoscopic analysis of hair count was done at a specific distance from left medial eyebrow; the hair density was noted; images were taken and recorded. PRP was prepared by Manual Double Spin method; Under local anaesthesia, both spray technique and microdermabrasion injection technique were done. The procedure was repeated every 3 months and dermoscopy was done at each visit at the fixed site. Statistical analysis was done with ANOVA test and paired t test for these groups.RESULTS83% had decrease in hair fall and 72% reported increase in hair growth at 3 months. Pain was the most common side effect. There was significant increase in hair density at each visit and there was negative correlation between duration of disease and increase in hair density.

Does microneedling with 5% minoxidil offer added advantage for treatment of androgenetic alopecia in comparison to use of topical 5% minoxidil alone?

Background: Androgenetic alopecia is the most common cause of chronic hair loss. The FDA approved treatment for male androgenetic alopecia are Finasteride and Minoxidil. But many patients do not respond to these medications. Microneedling is a recent modality that releases several growth factors and enhances penetration of minoxidil, thereby promoting hair growth.Methods: 60 patients, aged 21-40 years, with androgenetic alopecia were divided into 2 groups. In group A, patients were subjected to microneedling twice monthly, immediately followed by application of topical 5% minoxidil solution over the scalp and then 1 ml twice daily. In group B, patients were treated with application of 1ml of topical 5% minoxidil solution over the scalp twice daily. The results were evaluated based on patient’s and physician’s assessment based on the standardized 7-point evaluation scale.Results: Patients in group A showed statistically significant improvement (p value<0.05) compared to group B. Headache and erythema were the most common side effects encountered in both the groups.Conclusions: Microneedling with 5% minoxidil is a safe, simple and cost-effective modality and is a promising treatment option for patients with androgenetic alopecia. It showed much better results when compared to use of topical 5% minoxidil solution alone.

Study of cutaneous manifestations of polycystic ovarian syndrome

Background: Polycystic ovarian syndrome (PCOS) is one of the most frequently encountered endocrine disorders that occurs in as many as 4 to 10% of women of reproductive age group. It presents with a series of skin changes including acne, hirsutism, seborrhea, androgenetic alopecia (AGA) and acanthosis nigricans. Aim of the study was to determine the prevalence and frequency of different cutaneous manifestations in PCOS patients and to correlate them with the degree of hormonal abnormalities.Methods: A total 100 patients with features of PCOS who presented to department of dermatology, gynecology (January 2018-December 2019) with cutaneous manifestations were recorded and diagnosis of PCOS was made using Rotterdam’s criteria. Pregnant women and diagnosed cases of any other endocrine disorder were excluded. Hirsutism was assessed using Ferriman-Gallwey score and AGA according to Ludwig’s classification. Serum hormonal profile including FSH, LH, prolactin, testosterone (free), DHEAS, TSH, FBS, fasting insulin were done. Insulin resistance was determined by calculating HOMA-IR score.Results: Among cutaneous manifestations of PCOS, hirsutism (85%) was the most common finding followed by acne (73%), seborrhea (50%), AGA (36%), acanthosis nigricans (29%) and acrochordons (9%). The most common hormonal abnormality was insulin resistance in 53% patients, followed by raised free testosterone in 19% and serum prolactin in 18% patients. A statistically significant association was present between AGA and insulin resistance, hirsutism and raised prolactin levels, seborrhea and raised body mass index (p < 0.05).Conclusions: Dermatological manifestations of PCOS play a significant role in making the diagnosis and constitute a substantial portion of the symptoms experienced by women with this syndrome.

A Study on Association between Androgenetic Alopecia and Cardiovascular Risk Factors in Males with History of Hair Fall.

Review of literature revealed that Androgenetic Alopecia (AGA) or Male Pattern Baldness (MPB) and Coronary Artery Disease (CAD) are closely associated. Few studies showed an increased incidence of certain factors such as family history of CAD, family history of baldness, hypertension, increased Body Mass Index (BMI), central obesity, hyperglycaemia, and dyslipidaemia in all men with MPB, which were considered as cardiovascular risk factors. Recently newer risk factors such as Serum Lipoprotein a (SL-a), serum homocysteine (SH), and serum adiponectin are reported. A meta-analysis study showed that vertex type of baldness is more commonly associated with CAD. We wanted to study the association between androgenetic alopecia and cardiovascular risk factors in male patients with history of hair fall and family history of coronary artery disease.METHODSThis study was done among 136 men aged between 20 and 65 years with the history of hair fall and a family history of coronary artery disease. In all the subjects, blood pressure and pulse rate were recorded. Lipid profile and fasting blood sugar were done. Other parameters such as weight, height, BMI, waist circumference, and the pattern of baldness were documented.RESULTSIn majority of the subjects, 42.6 % belonged to the age group of 45-65 years with mean age of 48.63 years. Vertex type of baldness was observed in 78 persons constituting 57.3%. Among the grades of baldness, Grade - IV, V, and VI baldness were observed in majority of the subjects in the age group of 31-40 years. 73.0 % of persons with vertex type had positive family history of baldness and family history suggestive of ischemic heart disease. All subjects with vertex type had more cardiovascular risk factors in comparison to none type such as total Cholesterol, low LDL, high VLDL, and TC/HDL more than 5 and diabetes. Hence vertex type may be considered as a marker for the evaluation of well-known cardiovascular risk factors.CONCLUSIONSAll persons having history of hair fall and MPB especially vertex type should be evaluated for the well-known cardiovascular risk factors and should be advised to have periodical tests to be done to reduce the co-morbidity associated with increased cardiovascular risk factors.

Association of Dyslipidemia and Androgenetic Alopecia: A Case Control Study

Introduction: The association between androgenetic alopeciaand metabolic sydrome has been studied in past with variableresults. In the present study we evaluate the association ofandrogenetic alopecia with dyslipidemia.Material and methods: A prospective hospital based casecontrol study including 100 newly clinically diagnosed malepatients of androgenetic alopecia and age and sex matchedcontrol group was conducted for a period of one year. Lipidprofile including total cholesterol (TC), triglyceride (TG),high density lipoprotein (HDL), low density lipoproteins(LDL) were measured and compared in both the groups.Results: Of the 100 male AGA patients (age range 21-50,mean 34.49), 36 had grade II AGA, 24 had grade III AGA, 20had grade IV AGA, 15 had grade V AGA and 5 had grade VIAGA. Among AGA patients, 60 patients had mild-moderateAGA and 40 patients had severe AGA. Dyslipidemia wasfound to be statistically significantly more common inAGA patients as compared to the control group. The studyalso observed that deranged lipid profile was statisticallysignificantly more common in patients with severe AGA ascompared to patients with mild- moderate AGA.Conclusion: In the present study, dyslipidemia was foundto be more common in patients of androgenetic alopeciaas compared to controls and more common in those withsevere grades suggesting that androgenetic alopecia patientsespecially with severe grades are at higher risk of developingderanged serum lipids and should thus be evaluated fordyslipidemia and other cardiovascular co morbidities.

Pathogenesis of androgenetic alopecia / 中华皮肤科杂志

Androgenetic alopecia (AGA) is the most common type of non-cicatricial alopecia.Many researches have indicated that the pathogenesis of AGA involves genetic background,abnormal metabolism of sex hormones and follicle miniaturization,hair follicle microintlammation and environmental factors.Among them,genetic susceptibility is the most important factor for the individual difference of AGA,and follicle miniaturization induced by abnormal sex hormone metabolism and/or hair follicle microinflammation is the last step in the occurrence of AGA.

Efficacy of a Hair Tonic Containing Human Umbilical Cord Blood Mesenchymal Stem Cell-derived Conditioned Media in Patients with Androgenetic Alopecia / 대한피부과학회지

BACKGROUND: The development of a safe and convenient agent that can promote hair growth in patients with androgenetic alopecia remains challenging. OBJECTIVE: This study was designed to investigate the efficacy of a newly developed hair tonic containing a human umbilical cord blood mesenchymal stem cell (hUCB-MSC)-derived conditioned medium in promoting hair growth. METHODS: This double-blind, placebo-controlled clinical study investigated the efficacy of a hair tonic containing an hUCB-MSC-derived conditioned medium in 30 patients with patterned hair loss. Treatment efficacy was determined using phototrichograms to evaluate the density, diameter, and hair growth rate at baseline levels and after 4, 8, and 16 weeks of treatment. RESULTS: The hair density in the group treated with the hair tonic significantly increased from 125.2 to 134.6 hairs/cm2 (p<0.05). In this same group, the thickness of hair also increased from 0.083 to 0.110 mm (p<0.05). Additionally, the hair growth rate increased from 0.285 to 0.338 mm/day (p<0.05). No severe adverse reactions were reported. CONCLUSION: A hair tonic containing an hUCB-MSC-derived conditioned medium could be a new effective alternative to treat patients with androgenetic alopecia.

The effectiveness of adding low-level light therapy to minoxidil 5% solution in the treatment of patients with androgenetic alopecia

Background: Androgenetic alopecia is the commonest type of alopecia affecting over half of men and women. Low-level light therapy is a new technique for stimulating hair growth in both genders. Aims: To overcome the shortcomings of previous epidemiological studies and a lack of controlled clinical trials on the subject, this study compared the effectiveness of adding low-level light therapy to minoxidil topical solution in the treatment of androgenetic alopecia in patients presenting to two skin clinics in Isfahan, Iran during 2014–2015. Materials and Methods: This clinical trial included 50 patients aged 17–45 presenting to Khorshid and Alzahra educational centers and skin diseases research center for androgenetic alopecia during 2014–2015. The patients were randomly divided into a control and a case group. The case group received topical minoxidil 5% solution plus low-level light therapy twice per day. The control group was given the same topical solution and a laser comb system that was turned off to act as a placebo. Changes in patients' hair density and diameter and its overall regrowth as well as their satisfaction with the treatment were assessed at months 0 (baseline), 3, 6, 9 and 12. Results: The percentage of recovery from androgenetic alopecia and the patients' satisfaction with their treatment were significantly higher in the case group compared to the control group. The patients' mean hair density and diameter were found to be higher in the case group after the intervention compared to the control group. Limitations: The study limitations included patient compliance, small sample size, patient insight due to novelty of the method and clinical judgement. Conclusion: As a new method of treatment, low-level light therapy can help improve the percentage of recovery from androgenetic alopecia and increase patients' satisfaction with their treatment.

Tratamento de alopecia androgenética masculina com drug delivery por microagulhamento / Treatment of male androgenetic alopecia with drug delivery by microneedling

A alopecia é um problema comum com importante impacto negativo na qualidade de vida de seus portadores. Devido í ausência de uma terapia totalmente eficaz para o tratamento de alopecia, o microagulhamento surge como uma promissora e efetiva alternativa para esta disfunção. O objetivo deste trabalho foi apresentar um protocolo de tratamento eficaz para tratar a alopecia androgenética a curto e médio prazo bem como expor a autopercepção do paciente através de análise subjetiva em relação ao tratamento realizado. Paciente do sexo masculino, com alopécia androgenética foi tratado com 6 sessões de microagulhamento associado í mescla manipulada estéril de ativo. Houve melhora de 75% em relação ao crescimento capilar e coloração dos fios e em relação a espessura dos fios observou-se melhora de 50%. O protocolo apresentado neste trabalho mostrou-se seguro, rápido e eficaz para a terapia de crescimento capilar a curto e médio prazo, pois os resultados se mantiveram por um perí­odo de 5 meses pós o termino do tratamento. (AU)

Alopecia is a common disorder with a significant negative impact on the quality of life of patients. Due to the absence of a totally effective therapy for the treatment of alopecia, microneedle appears as a promising and effective alternative for this dysfunction. The objective of this study was to present an effective treatment to treat androgenetic alopecia in the short and medium term as well as to expose the patient self-perception through subjective analysis in relation to the treatment. A male patient with androgenetic alopecia was treated with 6 microneedle sessions associated with the sterile manipulated blend of active material. We observed an improvement of 75% in relation to hair growth and yarn staining and, in relation to the yarn thickness, a 50% improvement was observed. The protocol presented in this study proved to be safe, fast and effective for capillary growth therapy in the short and medium term because the results were maintained for a period of 5 months after the end of the treatment. (AU)